{"id":163828,"date":"2019-01-21T09:55:02","date_gmt":"2019-01-21T08:55:02","guid":{"rendered":"https:\/\/innovationorigins.com\/?p=163828"},"modified":"2019-01-21T09:55:02","modified_gmt":"2019-01-21T08:55:02","slug":"gtxs-next-clinical-validation-for-paraplegia-patients-will-be-in-nijmegen-clinic","status":"publish","type":"post","link":"https:\/\/ioplus.nl\/archive\/en\/gtxs-next-clinical-validation-for-paraplegia-patients-will-be-in-nijmegen-clinic\/","title":{"rendered":"GTX’s next clinical validation for paraplegia patients will be in Nijmegen clinic"},"content":{"rendered":"

The successful treatment of patients with chronic paraplegia\u00a0by the Eindhoven based startup\u00a0GTX Medical<\/a> will get its next phase in 2020. The\u00a0company, co-founded by\u00a0Sjaak Deckers<\/a>, Gr\u00e9goire Courtine and Jocelyne Bloch, will perform a second clinical validation on three medical sites, one of which will be the Sint Maartenskliniek in Nijmegen<\/a>. This is what Sjaak Deckers told his audience at the weekly Innovation cafe at the Kazerne in Eindhoven last week.<\/p>\n

“The feasibility\u00a0study in Nijmegen will focus on 10 to 20 patients who were between 2 to 4 weeks after becoming paraplegic, to see if we can then get even stronger effects of curation than with the patients with a longer period of paraplegia.”<\/p>\n

\"SjaakThree patients with chronic paraplegia were able to walk thanks to precise electrical stimulation of their spinal cords via a wireless implant. In a double study published in\u00a0Nature<\/i>\u00a0<\/a>and\u00a0Nature Neuroscience<\/i>.<\/a>\u00a0Swiss scientists Gr\u00e9goire Courtine (EPFL<\/a> and CHUV\/Unil<\/a>) and Jocelyne Bloch (CHUV\/Unil) have shown in October 2018 that after a few months of training, the patients were able to control previously paralyzed leg muscles, even in the absence of electrical stimulation.<\/p>\n

More about this breakthrough here<\/strong><\/em><\/a><\/p>\n

GTX Medical will use these findings to develop tailored neurotechnology to turn this rehabilitation paradigm into a treatment available at hospitals and clinics everywhere. \u201cWe are building next-generation neurotechnology that will also be tested very early post-injury when the potential for recovery is high and the neuromuscular system has not yet undergone the atrophy that follows chronic paralysis. Our goal is to develop a widely accessible treatment,\u201d says Courtine in October.<\/p>\n

GTX Medical is based in Eindhoven and Lausanne, with the majority of the staff on the High Tech Campus Eindhoven, Deckers’ home town.\u00a0Deckers said that it is “almost impossible” to find the right talents in the Eindhoven region, especially because companies like ASML and Philips are scouting for the same sort of employees: developers and engineers in electronics firmware and embedded software. “So we have to keep looking for talents outside the Netherlands and even outside Europe.” GTX now employs 55 people from 14 nationalities.<\/p>\n

Still, Deckers thinks Eindhoven is the right place to be, because of the useful network he has there, the presence of investors and “if only because\u00a0it is only half as expensive as Switzerland, where Courtine and his colleagues are located”.<\/p>\n